vs

Side-by-side financial comparison of MediWound Ltd. (MDWD) and VerifyMe, Inc. (VRME). Click either name above to swap in a different company.

MediWound Ltd. is the larger business by last-quarter revenue ($5.7M vs $5.0M, roughly 1.1× VerifyMe, Inc.). VerifyMe, Inc. runs the higher net margin — -66.7% vs -233.3%, a 166.6% gap on every dollar of revenue. On growth, MediWound Ltd. posted the faster year-over-year revenue change (12.7% vs -7.4%).

MediWound Ltd. is a biopharmaceutical company specializing in the research, development, production and commercialization of innovative products for burn care, chronic wound treatment and soft tissue repair. It operates mainly across North America, Europe and Asia, serving hospitals, healthcare providers and patients in the wound care segment.

VerifyMe, Inc. is a technology provider specializing in identity verification, anti-counterfeiting, and brand protection solutions. Its offerings include secure authentication tools, supply chain traceability systems, and customer engagement platforms, serving consumer goods, pharmaceutical, and retail sectors across North America and select global markets.

MDWD vs VRME — Head-to-Head

Bigger by revenue
MDWD
MDWD
1.1× larger
MDWD
$5.7M
$5.0M
VRME
Growing faster (revenue YoY)
MDWD
MDWD
+20.1% gap
MDWD
12.7%
-7.4%
VRME
Higher net margin
VRME
VRME
166.6% more per $
VRME
-66.7%
-233.3%
MDWD

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
MDWD
MDWD
VRME
VRME
Revenue
$5.7M
$5.0M
Net Profit
$-13.3M
$-3.4M
Gross Margin
23.5%
41.2%
Operating Margin
-100.1%
-68.2%
Net Margin
-233.3%
-66.7%
Revenue YoY
12.7%
-7.4%
Net Profit YoY
-111.2%
-38.4%
EPS (diluted)
$-1.23
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDWD
MDWD
VRME
VRME
Q3 25
$5.0M
Q2 25
$5.7M
$4.5M
Q1 25
$4.5M
Q3 24
$5.4M
Q2 24
$5.1M
$5.4M
Q1 24
$5.8M
Q4 23
$8.7M
Q3 23
$5.6M
Net Profit
MDWD
MDWD
VRME
VRME
Q3 25
$-3.4M
Q2 25
$-13.3M
$-291.0K
Q1 25
$-571.0K
Q3 24
$-2.4M
Q2 24
$-6.3M
$-346.0K
Q1 24
$-553.0K
Q4 23
$2.0K
Q3 23
$-930.0K
Gross Margin
MDWD
MDWD
VRME
VRME
Q3 25
41.2%
Q2 25
23.5%
35.2%
Q1 25
33.4%
Q3 24
34.9%
Q2 24
8.8%
39.1%
Q1 24
39.2%
Q4 23
33.0%
Q3 23
36.5%
Operating Margin
MDWD
MDWD
VRME
VRME
Q3 25
-68.2%
Q2 25
-100.1%
-7.1%
Q1 25
-13.3%
Q3 24
-52.8%
Q2 24
-88.6%
-10.0%
Q1 24
-11.2%
Q4 23
0.8%
Q3 23
-15.3%
Net Margin
MDWD
MDWD
VRME
VRME
Q3 25
-66.7%
Q2 25
-233.3%
-6.4%
Q1 25
-12.8%
Q3 24
-44.6%
Q2 24
-124.5%
-6.5%
Q1 24
-9.6%
Q4 23
0.0%
Q3 23
-16.6%
EPS (diluted)
MDWD
MDWD
VRME
VRME
Q3 25
$-0.26
Q2 25
$-1.23
$-0.02
Q1 25
$-0.05
Q3 24
$-0.23
Q2 24
$-0.68
$-0.03
Q1 24
$-0.05
Q4 23
$0.00
Q3 23
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDWD
MDWD
VRME
VRME
Cash + ST InvestmentsLiquidity on hand
$1.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$20.1M
$11.1M
Total Assets
$67.0M
$13.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDWD
MDWD
VRME
VRME
Q3 25
Q2 25
$1.1M
Q1 25
Q3 24
$2.6M
Q2 24
$3.8M
$2.9M
Q1 24
$2.8M
Q4 23
$3.0M
Q3 23
$2.9M
Total Debt
MDWD
MDWD
VRME
VRME
Q3 25
Q2 25
Q1 25
Q3 24
$500.0K
Q2 24
$600.0K
Q1 24
$800.0K
Q4 23
$875.0K
Q3 23
$1.0M
Stockholders' Equity
MDWD
MDWD
VRME
VRME
Q3 25
$11.1M
Q2 25
$20.1M
$14.4M
Q1 25
$14.6M
Q3 24
$10.3M
Q2 24
$17.9M
$12.3M
Q1 24
$12.4M
Q4 23
Q3 23
$11.9M
Total Assets
MDWD
MDWD
VRME
VRME
Q3 25
$13.3M
Q2 25
$67.0M
$17.2M
Q1 25
$17.1M
Q3 24
$14.8M
Q2 24
$57.3M
$17.5M
Q1 24
$17.9M
Q4 23
$20.7M
Q3 23
$18.8M
Debt / Equity
MDWD
MDWD
VRME
VRME
Q3 25
Q2 25
Q1 25
Q3 24
0.05×
Q2 24
0.05×
Q1 24
0.06×
Q4 23
Q3 23
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDWD
MDWD
VRME
VRME
Operating Cash FlowLast quarter
$-5.8M
$243.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDWD
MDWD
VRME
VRME
Q3 25
$243.0K
Q2 25
$-5.8M
$710.0K
Q1 25
$-404.0K
Q3 24
$-10.0K
Q2 24
$-3.6M
$372.0K
Q1 24
$-60.0K
Q4 23
$843.0K
Q3 23
$-136.0K
Free Cash Flow
MDWD
MDWD
VRME
VRME
Q3 25
Q2 25
Q1 25
Q3 24
$-12.0K
Q2 24
$369.0K
Q1 24
$-62.0K
Q4 23
$840.0K
Q3 23
FCF Margin
MDWD
MDWD
VRME
VRME
Q3 25
Q2 25
Q1 25
Q3 24
-0.2%
Q2 24
6.9%
Q1 24
-1.1%
Q4 23
9.6%
Q3 23
Capex Intensity
MDWD
MDWD
VRME
VRME
Q3 25
Q2 25
Q1 25
Q3 24
0.0%
Q2 24
0.1%
Q1 24
0.0%
Q4 23
0.0%
Q3 23
0.0%
Cash Conversion
MDWD
MDWD
VRME
VRME
Q3 25
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q4 23
421.50×
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDWD
MDWD

Segment breakdown not available.

VRME
VRME

Proactive Services$4.2M83%
Other$869.0K17%

Related Comparisons